On November 2, 2019 Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, reported that it will host its capital markets day on November 12 and is pleased to invite investors, analysts and press to presentations by the members of the company’s executive management team and by Ulrich Granzer, PhD, founder of Granzer Regulatory Consulting & Services (Press release, Vaccibody, NOV 2, 2019, View Source [SID1234550196]). Granzer has a wide range of experience in all aspects of drug development and regulatory affairs, with particular focus on bringing novel therapies to market.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Venue: Forskningsparken, Gaustadalléen 21, 0349 Oslo. Meeting room Faros.
Date: Tuesday, 12th November 2019
Agenda:
14.00-14.10 Introduction Michael Engsig
14.10-15.00 Update on the VB N-01 study including the clinical data Agnete Fredriksen
15.00-15.45 Status of the cancer vaccine field and development of novel immunotherapies Ulrich Granzer
15.45-16.05 Company update Michael Engsig
16.05-16.30 Questions & Answers All
16.30-17.30 Mingling, snacks and drinks All